IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0093070.html
   My bibliography  Save this article

Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials

Author

Listed:
  • Mourad Tighiouart
  • Yuan Liu
  • André Rogatko

Abstract

Escalation with overdose control (EWOC) is a Bayesian adaptive phase I clinical trial design that produces consistent sequences of doses while controlling the probability that patients are overdosed. However, this design does not take explicitly into account the time it takes for a patient to exhibit dose limiting toxicity (DLT) since the occurrence of DLT is ascertained within a predetermined window of time. Models to estimate the Maximum Tolerated Dose (MTD) that use the exact time when the DLT occurs are expected to be more precise than those where the variable of interest is categorized as presence or absence of DLT, given that information is lost in the process of categorization of the variable. We develop a class of parametric models for time to toxicity data in order to estimate the MTD efficiently, and present extensive simulations showing that the method has good design operating characteristics relative to the original EWOC and a version of time to event EWOC (TITE-EWOC) which allocates weights to account for the time it takes for a patient to exhibit DLT. The methodology is exemplified by a cancer phase I clinical trial we designed in order to estimate the MTD of Veliparib (ABT-888) in combination with fixed doses of gemcitabine and intensity modulated radiation therapy in patients with locally advanced, un-resectable pancreatic cancer.

Suggested Citation

  • Mourad Tighiouart & Yuan Liu & André Rogatko, 2014. "Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-13, March.
    • Handle: RePEc:plo:pone00:0093070
    DOI: 10.1371/journal.pone.0093070
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093070
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093070&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0093070?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Zacks, S. & Rogatko, A. & Babb, J., 1998. "Optimal Bayesian-feasible dose escalation for cancer phase I trials," Statistics & Probability Letters, Elsevier, vol. 38(3), pages 215-220, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Oron Assaf P. & Azriel David & Hoff Peter D., 2011. "Dose-Finding Designs: The Role of Convergence Properties," The International Journal of Biostatistics, De Gruyter, vol. 7(1), pages 1-17, October.
    2. Jay Bartroff & Tze Leung Lai, 2011. "Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs," Biometrics, The International Biometric Society, vol. 67(2), pages 596-603, June.
    3. Graham M. Wheeler, 2018. "Incoherent dose-escalation in phase I trials using the escalation with overdose control approach," Statistical Papers, Springer, vol. 59(2), pages 801-811, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0093070. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.